This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Knigge, U. Articles by Warberg, J. Search for Related Content PubMed PubMed Citation Articles by Knigge, U. Articles by Warberg, J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CIMETIDINE EPINEPHRINE HISTAMINE OXYTOCIN PYRILAMINE THIOUREA

Histaminergic and Catecholaminergic Interactions in the Central Regulation of Vasopressin and Oxytocin Secretion¹

Department of Medical Physiology, Division of Endocrinology and Metabolism, The Panum Institute (U.K., E.W., A.K., H.J., J.W.) and Department of Surgery C, Rigshospitalet (U.K.), University of Copenhagen, Blegdamsvej 3 C, DK-2200 Copenhagen N, Denmark

Address all correspondence and requests for reprints to: Ulrich Knigge, M.D., Ph.D., Department of Medical Physiology, Building 12–3, The Panum Institute, University of Copenhagen, Blegdamsvej 3 C, DK-2200 Copenhagen N, Denmark. E-mail: Knigge{at}mfi.ku.dk

Activation of histaminergic and noradrenergic/adrenergic neurons in the brain stimulates the release of the neurohypophysial hormones arginine vasopressin (AVP) and oxytocin (OT) and are involved the mediation of the hormone responses to physiological stimuli such as dehydration and suckling. We therefore investigated whether the two neuronal systems interact in their regulation of AVP and OT secretion in conscious male rats. When administered intracerebroventricularly (icv), histamine (HA) as well as the H1 receptor agonist 2-thiazolylethylamine or the H2 receptor agonist 4-methylHA stimulated AVP and OT secretion. Prior icv infusion of antagonists specific to or ß adrenergic receptors or their subtypes did not significantly affect the hormone response to HA or the histaminergic agonists. Infused icv norepinephrine (NE) or epinephrine (E) increased AVP and OT secretion. Prior icv infusion of the H1 receptor antagonist mepyramine or the H2 receptor antagonist cimetidine significantly inhibited the AVP and OT responses to NE and the AVP response to E, whereas only cimetidine inhibited the OT response to E significantly. Systemic pretreatment with imetit, which by activation of presynaptic H3 receptors inhibits neuronal synthesis and release of HA, decreased the AVP and OT responses to NE and E significantly. In the doses used, HA and E had no significant effect on mean arterial blood pressure. NE increased mean arterial blood pressure 10% at 1 and 2.5 min, whereafter the blood pressure returned to basal level within 10 min. The results indicate that noradrenergic and adrenergic neurons stimulate AVP and OT secretion via an involvement of histaminergic neurons, which may occur at magnocellular neurons in the supraoptic and paraventricular nuclei of the hypothalamus. The stimulatory effect of the amines on neurohypophysial hormone secretion seems to be independent of a central action on blood pressure. In contrast, a functionally intact noradrenergic and adrenergic neuronal system seems not to be a prerequisite for a HA-induced release of AVP and OT. The present findings further substantiate the role of histaminergic neurons in the central regulation of neurohypophysial hormone secretion.

This article has been cited by other articles:

				H. L. Haas, O. A. Sergeeva, and O. Selbach Histamine in the Nervous System Physiol Rev, July 1, 2008; 88(3): 1183 - 1241. [Abstract] [Full Text] [PDF]

				K. J. Damjanoska, N. A. Muma, Y. Zhang, D. N. D'Souza, F. Garcia, G. A. Carrasco, G. H. Kindel, K. A. Haskins, M. Shankaran, B. R. Petersen, et al. Neuroendocrine Evidence That (S)-2-(Chloro-5-fluoro-indol- l-yl)-1-methylethylamine Fumarate (Ro 60-0175) Is Not a Selective 5-Hydroxytryptamine2C Receptor Agonist J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1209 - 1216. [Abstract] [Full Text] [PDF]